Hims & Hers Health (NYSE:HIMS) Trading Down 6.2% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) traded down 6.2% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $28.98 and last traded at $28.59. 9,500,766 shares were traded during trading, a decline of 39% from the average session volume of 15,661,397 shares. The stock had previously closed at $30.47.

Specifically, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the completion of the transaction, the chief financial officer directly owned 91,617 shares in the company, valued at $2,779,659.78. This represents a 9.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Ratings Changes

A number of brokerages have weighed in on HIMS. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Evercore ISI began coverage on Hims & Hers Health in a report on Monday, January 12th. They set an “in-line” rating and a $33.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Bank of America increased their target price on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research report on Tuesday, November 4th. Finally, Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $44.54.

Hims & Hers Health Stock Down 2.9%

The stock has a 50-day moving average price of $34.95 and a 200-day moving average price of $45.08. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company has a market capitalization of $6.74 billion, a P/E ratio of 54.86, a P/E/G ratio of 5.17 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same period in the prior year, the business earned $0.32 EPS. Hims & Hers Health’s quarterly revenue was up 49.2% on a year-over-year basis. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Institutional Trading of Hims & Hers Health

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 4.5% during the third quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock valued at $1,107,062,000 after purchasing an additional 844,991 shares during the period. Capital World Investors grew its stake in shares of Hims & Hers Health by 1.2% in the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC increased its position in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares in the last quarter. State Street Corp raised its stake in Hims & Hers Health by 1.9% during the 3rd quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after buying an additional 132,384 shares during the period. Finally, Geode Capital Management LLC raised its stake in Hims & Hers Health by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock worth $236,622,000 after buying an additional 71,593 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.